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Supplemental Table 1. XCMS online parameter settings. 
Parameter group Parameter Setting 
Feature detection ppm 15 
 min peak width 5 
 max peak width 10 
Alignment min frac 0.1 
 bw 3 
 m/z width 0.015 
Retention time correction method Obiwarp 
 profStep 1 
 
  




Supplemental Figure 1. Correlation of quantitative concentrations of 6-oxoPIP and 2-OPP in plasma (X-



















































































Supplemental Figure 2. Within-sample correlation for 2-OPP and 6-oxoPIP levels in urine, plasma and 
CSF of PDE-ALDH7A1 patients. While for urine, there appeared to be a positive correlation between 2-
OPP and 6-oxoPIP levels, in plasma and CSF this was not clear. Different treatment regimens in patients 
are coded as follows: open circles: untreated; filled squares: vitamin B6 supplementation; filled circles: 
vitamin B6 and arginine supplementation; filled triangles: vitamin B6 supplementation and lysine 










Supplemental Figure 3. Correlation of 6-oxoPIP and 2-OPP concentration to α-AASA concentration in urine 











































































Supplemental Figure 4. (A) Overlay of IR spectra of the protonated 2S,6S-2-OPP ion measured from 
incubations of P6C and AcAc in plasma, urine, H2O and PBS, incubation of P6C in ketotic urine and from a 
solution of the synthetic reference standard. (B) Overlay of IR spectra of the protonated 2S,6R-2-OPP ion 









Supplemental Figure 5. Massive ketosis does not lead to false positive PDE-ALDH7A1 diagnosis based on 
2-OPP levels in plasma. In plasma of 6 non-PDE-ALDH7A1 control individuals in massive ketosis, based on 
highly increased acetyl(C2)-carnitine concentrations (upper reference limit C2-carnitine is 9.0 μmol/L), no 
correlation between C2-carnitine levels (X-axis) and 2-OPP levels (Y-axis) could be detected. Also, 2-OPP 


































Supplemental Figure 6. Extracted ion chromatograms of 2S,6R-2-OPP (m/z 186.1123, RT 2.67 min) in full 
body lysates of zebrafish exposed to increasing concentrations of 2S,6R-2-OPP in the swimming water; 
(A) Negative control, H2O exposure, (B) 1 μM, (C) 10 μM, (D) 100 μM, (E) 1 mM and (F) 10 mM 2-OPP 
exposure. Y-axis represents relative NGMS intensity, X-axis represents RT (min). 
 
  




Supplemental Figure 7. Direct infusion MS results in DBS for 6-oxoPIP and 2-OPP, showing complete 
overlap between PDE patients and controls for 6-oxoPIP, but adequate distinction based on 2-OPP. Y-axis 
shows intensity of 6-oxoPIP in the left figure and 2-OPP in the right figure. On the X-axis, the categories of 
non-PDE controls (controls, N=10) and PDE-ALDH7A1 patients (PDE, N=4) are plotted. Patient results are 
marked as follows: Stars: neonatal DBS, untreated patients; filled square: DBS from 10-year old patient on 





































































Supplemental Figure 8. Synthesis of 2-OPP, 1,3-13C2-(2S,6R)-2-OPP and 13C1-6-oxoPIP; reagents (1-14) and 
reaction conditions (a-m): (1) α-amino adipic acid, (2) (S)-6-oxopiperidine-2-carboxylic-6-13C acid (6-
oxoPIP), (3) tert-butyl acetoacetate, (4) acetoacetate, (5) allysine ethylene acetal, (6) (S)-2,3,4,5-
tetrahydropyridine-2-carboxylic acid (P6C), (7) benzyl (2S)-1-benzyl-6-(2-oxo-propyl) piperidine-2-
carboxylate, (8) (2S)-6-(2-oxopropyl)piperidine-2-carboxylic acid (2-OPP), (9) acetone-1,3-13C2, (10) tert-
butyldimethyl(prop-1-en-2-yloxy)silane 13C2, (11) benzyl 2-(((benzyloxy)carbonyl)amino)-5-(1,3-dioxolan-
2-yl)pentanoate, (12) (S)-1-((benzyloxy)carbonyl)-1,2,3,4-tetrahydropyridine-2-carboxylic acid, (13) 
dibenzyl (2S)-6-(2-oxopropyl-1,3-13C2)piperidine-1,2-dicarboxylate, (14) (2S)-6-(2-oxopropyl-1,3-
13C2)piperidine-2-carboxylic acid, (a) AcOH, 120 oC, 95%; (b) TFA, DCM, 96%; (c) 1M HCl, quant; (d) H2O (pH 
6-7); (e) BnBr, K2CO3, DMF, 40% over two steps; (f) H2, Pd/C, ACN, 54%; (g) TBDMSOTf, 0 oC, DCM, 92%; (h) 
CbzOsu, NaHCO3, dioxane/H2O; (i) BnBr, K2CO3, DMF, 85% over two steps; (j) p-TsOH, DMF, toluene, 115 
oC, 94%; (k) AcCl, MeOH, 99%; (l) Sn(OTf)2, MeCN, -30 oC to room temperature, 79%; (m) H2, Pd/C, 
MeOH/H2O, 76%. The * denotes the position of the 13C isotope label. Please refer to supplemental 









Supplemental Figure 9. 1H and 13C NMR spectra of compounds 2, 7, 8 and 10-14 as shown in Supplemental 
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1H and 13C NMR spectra and (LC) MS measurements in model compound synthesis 
 
1H and 13C NMR spectra (Supplemental Figure 9) were recorded on a Bruker AVANCE III (500 MHz 1H, 
125 MHz 13C) or) equipped with a Bruker Prodigy BB cryoprobe or a Bruker AVANCE III (400 MHz 1H, 
100 MHz 13C in the solvent indicated at room temperature (RT). Chemical shifts are reported in δ (ppm) 
units relative to the internal reference tetramethylsilane (Me4Si). For 1H NMR spectra, the following 
abbreviations are used to describe multiplicities: s (singlet), d (doublet), t (triplet), bs (broad singlet), dd 
(double doublet), and m (multiplet). Coupling constants are reported in Hertz (Hz) as a J value, for 13C 
labelled compounds a distinction is made between 1J and 3J couplings. Mass spectra were recorded on 
Thermo Finnigan LCQ Advantage Max. LC-MS was carried out on a Shimadzu LCMS-QP8000 (Duisburg, 
Germany) single quadrupole bench-top mass spectrometer operating in a positive ionization mode. The 
scanning range was m/z 50-2000. A gradient of MeCN/H2O containing 0.1 % formic acid was used. Samples 
were injected using a flow rate of 0.2 mL/min and eluted with 5-100 % in 50 min, infused in the 
Electrospray system. All compounds were routinely checked by TLC on Kieselgel 60 F254 (Merck, 
Darmstadt, Germany); spots were visualized under UV light (254 nm) and were stained with ninhydrin, 2-
4-ninitrophenylhydrazine (DNP), Cerium Molybdate Stain or aqueous KMnO4 (depending on the reaction), 
followed by heating on a hot plate. Rf values were obtained with the indicated solvent mixtures. All 
solvents were reagent grade and, when necessary, were purified and dried by standard methods. Organic 
solutions were dried over anhydrous sodium sulfate and anhydrous magnesium sulfate. The yields of the 
samples were calculated after drying the samples under high vacuum overnight or after lyophilization. All 
commercially purchased reagents were used without further purification as delivered from the 
corresponding companies. (S)-2-Aminohexanedioic-6-13C acid, tert-butylacetoacetate, Sn(OTf)2 and 
acetone-1,3-13C2  were obtained  from Sigma Aldrich. Allysine ethylene acetal was obtained from Chiralix. 
TBDMSOTf and CbzOSU were obtained from Fluorochem. 
 
Detailed information on synthesis as shown in Supplemental Figure 8, and characteristics for NMR spectra 
as shown in Supplemental Figure 9.  
Numbers in brackets refer to compounds as shown in Supplemental Figure 7. Superscript numbers in 








(S)-6-Oxopiperidine-2-carboxylic-6-13C acid [2] (1) 
(S)-2-Aminohexanedioic-6-13C acid (2.15 mg, 13.3 µmol) was dissolved in AcOH (200 µL) and refluxed for 6 
h. The solution was cooled to RT, concentrated under reduced pressure, dissolved in water and lyophilized 
to obtain 1.81 mg of 2 (12.6 µmol, 95%) as a white solid. 1H NMR (500 MHz, DMSO-d6) δ 7.34 (s, 1H), 3.88 
(qd, J = 5.6, 2.3 Hz, 1H), 2.19 – 2.06 (m, 2H), 2.03 – 1.89 (m, 1H), 1.78 – 1.70 (m, 1H), 1.69 – 1.59 (m, 2H); 
13C NMR (126 MHz, DMSO-d6) δ 173.7, 55.0, 31.0, 25.2, 18.7. 
 
Acetoacetic acid [4] (2)  
TFA (15 mL, 190 mmol) was added to an ice-cold solution of tert-butylacetoacetate (10 mL, 61 mmol) in 
DCM (15 mL). The solution was allowed to warm up after 5 min and continuously stirred for 1 h. The 
solution was concentrated in vacuo to obtain 6.0 g of acetoacetic acid in 96% yield (59 mmol), used as is 
without further purification. RF = 0.30 (1:1, EtOAc:heptane).   
 
(S)-2,3,4,5-Tetrahydropyridine-2-carboxylic acid, P6C [6] 
For the incubations: To a suspension of allysine ethylene acetal (200 mg) in water (5 mL) was added 800 
mg Amberlyst-15. After complete conversion the Amberlyst resin was washed with water (2 x 5 mL), 
subsequently the P6C was eluted with 10 mL 25% ammonia solution and dried in vacuo at ambient 
temperature.(3) The resulting solid was reconstituted to a 1 mM solution used in the incubations.  
For synthesis: allysine ethylene acetal (4.0 g) was dissolved in 1 M HCl (42 mL). After complete conversion 
the resulting solution was used as is for the synthesis of 7. 
 
Benzyl (2S)-1-benzyl-6-(2-oxopropyl)piperidine-2-carboxylate [7]  
A solution of acetoacetic acid (4) (6.0 g, 59 mmol) in water (20 mL) was neutralized to pH 7 with solid 
NaOH. The acidic solution of 6 was added dropwise to the mixture while keeping the pH between 6 and 7 
with addition of 1 M NaOH. After the solution (pH = 6.5) was stirred overnight it was refluxed for 30 min 
and subsequently concentrated in vacuo. Hot filtration with ethanol resulted in 3.9 g of a crude mixture 
containing 8.(4) To facilitate purification, the residue was derivatized. The resulting residue was redissolved 
in DMF (60 mL) and cooled to 0 oC. Solid K2CO3 (15 g, 11 mmol) was added followed by the addition of BnBr 
(10 mL, 84 mmol). The resulting mixture was stirred overnight and concentrated in vacuo. The residue was 
taken up in EtOAc (50 mL), washed with water (10 mL) and brine (10 mL), dried over MgSO4 and 
concentrated in vacuo. Purification by column chromatography (3% diethyl ether in toluene) yielded 3.2 g 
of a slightly red oil in 42% yield (21 mmol) of both stereoisomers in a ratio of 1:0.6 (cis:trans, assignment 




of diastereomers based on NMR 8). RF = 0.29 (1:3, EtOAc:heptane); 1H NMR (400 MHz, CDCl3, both 
stereoisomers; integrals based on major stereoisomer) δ 7.50 – 7.03 (m, 18H), 5.13 (s, 2H), 5.05 (d, J = 2.1 
Hz, 1H), 3.82 (d, J = 14.3 Hz, 1H), 3.77 (s, 1H), 3.75 – 3.67 (m, 1H), 3.62 (d, J = 14.3 Hz, 1H), 3.53 (t, J = 4.8 
Hz, 1H), 3.38 (dd, J = 7.6, 4.3 Hz, 0.6H), 3.17 (s, 0.6H), 2.79 – 2.68 (m, 1.6H), 2.42 – 2.31 (m, 2H), 2.08 (s, 
3H), 1.92 (s, 1.8 H), 1.90 – 1.71 (m, 3H), 1.70 – 1.57 (m, 3H), 1.52 – 1.24 (m, 4.5H); 13C NMR (126 MHz, 
Chloroform-d) δ 174.6, 173.2, 139.6, 128.5, 128.4, 128.30, 128.29, 128.23, 128.21, 128.17, 66.3, 66.1, 63.2, 
60.1, 57.5, 55.6, 54.1, 52.2, 47.6, 46.7, 30.4, 30.2, 29.9, 28.4, 26.0, 20.32, 20.26; HRMS (ESI+); calcd for 
C23H28NO3 (M+H+): 366.2069, found 366.2081. 
 
(2S)-6-(2-Oxopropyl)piperidine-2-carboxylic acid [8, 2-OPP] 
A solution of 7 (623 mg, 1.70 mmol) in MeCN (10 mL) was purged with argon. Pd/C (181 mg, 0.17 mmol) 
was added and the atmosphere was exchanged to H2. After almost complete conversion (~ 1.5 h) the 
mixture was filtered over celite and concentrated in vacuo. The residue was purified by chromatography 
on Iatro beads (0 -> 40% MeOH in DCM) to yield 172 mg of an off white solid (55%, 0.93 mmol). 1H NMR 
(500 MHz, D2O, both diastereoisomers; integrals based on major stereoisomer) δ 3.96 (t, J = 5.0 Hz, 1H), 
3.94 – 3.85 (m, 1H), 3.66 (dd, J = 12.5, 3.3 Hz, 0.65H), 3.61 (dtd, J = 12.3, 6.3, 2.9 Hz, 0.65H), 3.13 – 2.92 
(m, 3.4H), 2.27 (s, 5.7H), 2.18 – 2.09 (m, 1H), 2.03 – 1.82 (m, 3.4H), 1.80 – 1.71 (m, 1H), 1.70 – 1.39 (m, 
4H); 13C NMR (126 MHz, D2O, both stereoisomers) δ 211.9, 210.7, 174.3, 173.4, 60.2, 56.1, 52.3, 49.5, 45.5, 
44.3, 29.6, 29.5, 27.6, 27.1, 26.2, 24.7, 22.1, 18.5; HRMS (ESI+); calcd for C9H16NO3 (M+H+): 186.1130, found 
186.1130. 
 
tert-Butyldimethyl(prop-1-en-2-yloxy)silane 13C2 [10] (5)  
A flame dried flask was charged with dry DCM (10 ml) and acetone-1,3-13C2 (200 mg, 3.33 mmol). The 
solution was cooled with an ice-bath and TEA (550 µL, 4.00 mmol) was added. After 1 h at RT, the solution 
was cooled with an ice-bath and TBDMSOTf (841 µL, 3.66 mmol) was added dropwise. After stirring at RT 
for 4 h, the reaction was quenched with cold sat. aq. NH4Cl (5 mL). The mixture was extracted with Et2O 
(15 mL), dried over MgSO4 and concentrated under reduced pressure. The resulting non –viscous clear 
liquid was separated by means of pipet from the solids and viscous red oil resulting in 530 mg of 10 (3.06 
mmol) in 92% yield. 1H NMR (500 MHz, chloroform-d) δ 4.24 – 4.20 (m, 1H), 3.93 – 3.90 (m, 1H), 1.77 (ddd, 
1JCH = 126,7 Hz, 3J = 3.9, 0.9 Hz, 3H), 0.95 (s, 9H), 0.18 (s, 6H); 13C NMR (126 MHz, Chloroform-d) δ 91.3, 
91.2, 25.7, 22.8, 22.7, -4.6. 
 




Benzyl 2-(((benzyloxy)carbonyl)amino)-5-(1,3-dioxolan-2-yl)pentanoate [11] (6)  
A suspension of (S)-2-amino-5-(1,3-dioxolan-2-yl)pentanoic acid (2.00 g, 10.6 mmol) in dioxane/water (10 
mL, 1:1) was cooled with an ice bath and subsequently NaOH (444 mg, 11.1 mmol), NaHCO3 (1.33 g,  15.9 
mmol) and CbzOSu (2.69 g, 10.8 mmol) were added. After stirring overnight, dioxane was removed under 
reduced pressure. The resulting solution was diluted with a 2.5% NaHCO3 solution (100 mL) and washed 
with Et2O (3 x 25 mL). The basic aqueous layer was acidified with 6M HCl solution until precipitation was 
observed (pH ~ 3). The resulting precipitate was extracted with EtOAc (3 x 50 mL), dried over MgSO4 and 
concentrated under reduced pressure. The resulting transparent oil was dissolved in dry DMF (20 mL) and 
cooled with an ice bath. Subsequently K2CO3 (1.53 g, 11.1 mmol) and BnBr (1.88 mL, 15.9 mmol) were 
added. The reaction mixture was stirred overnight at RT. After complete conversion water (100 mL) was 
added followed by extraction with EtOAc (3 x 50 mL). The organic layer was washed with brine (50 mL), 
dried over MgSO4 and concentrated under reduced pressure. The resulting residue was purified by column 
chromatography (heptane:EtOAc = 2:1) to yield 4.03 g of a transparent oil (10.6 mmol, 85%). RF = 0.29 (1:3, 
EtOAc:heptane); 1H NMR (400 MHz, Chloroform-d) δ 7.39 – 7.28 (m, 10H), 5.29 (d, J = 8.2 Hz, 1H), 5.24 – 
5.13 (m, 2H), 5.10 (s, 2H), 4.79 (t, J = 4.6 Hz, 1H), 4.43 (q, J = 7.7, 7.1 Hz, 1H), 3.98 – 3.75 (m, 4H), 1.97 – 
1.83 (m, 1H), 1.79 – 1.60 (m, 3H), 1.47 (m, 2H); 13C NMR (126 MHz, Chloroform-d) δ 128.8, 128.7, 128.6, 
128.4, 128.3, 128.2, 104.2, 67.3, 67.1, 65.01, 65.00, 54.1, 33.4, 32.6, 19.8; HRMS (ESI+): calcd for 
C32H27NNaO6 (M+Na+): 374.1368, found 374.1369 
 
(S)-1-((Benzyloxy)carbonyl)-1,2,3,4-tetrahydropyridine-2-carboxylic acid [12] (6)  
To a solution of 11 (2.60 g, 6.3 mmol) in toluene (25 mL) was added DMF (240 µL, 3.14 mmol) and 
pTsOH·H2O (120 mg 0.63 mmol). The solution was heated to reflux for 3 h. Upon complete conversion the 
reaction was cooled to RT, diluted with EtOAc (25 mL) and quenched with saturated aqueous NH4Cl (25 
mL). The layers were separated and the organic layer was washed with sat. aq. NaHCO3, dried over MgSO4 
and concentrated under reduced pressure. The resulting residue was purified by column chromatography 
(EtOAc:heptane = 1:4) resulting in 2.10 g of a colorless oil in 94% yield (6.29 mmol). RF = 0.45 (1:3, 
EtOAc:heptane); 1H NMR (500 MHz, DMSO-d6, rotamers) δ 7.40 – 7.24 (m, 10H), 6.84 – 6.76 (m, 1H), 5.23 
– 5.06 (m, 4H), 5.01 – 4.81 (m, 2H), 2.34 – 2.16 (m, 1H), 1.95 (dt, J = 17.6, 5.7 Hz, 1H), 1.87 (dddd, J = 18.8, 
10.1, 5.1, 2.1 Hz, 1H), 1.74 (m, 1H); 13C NMR (126 MHz, chloroform-d, rotamers) δ 170.4, 170.1, 152.6, 
152.5, 163.13, 136.07, 135.8, 135.7, 128.5, 128.42, 128.36, 128.10, 128.09, 128.07, 127.9, 127.71, 127.70, 
127.4, 124.1, 123.8, 105.8, 105.4, 67.1, 67.0, 66.34, 66.29, 55.7, 55.4, 23.13, 12.08, 17.9, 17.7; HRMS (ESI+): 
calcd for C21H21NNaO4 (M+Na+): 374.1368, found 374.1369. 





Dibenzyl (2S)-6-(2-oxopropyl-1,3-13C2)piperidine-1,2-dicarboxylate [13] 
To a solution of 12 (478 mg, 1.36 mmol) in dry MeOH (15 mL) was added AcCl (20 µL, 0.27 mmol) at RT. 
After stirring for 1h, the solution was diluted with DCM (5 ml) and quenched with saturated aqueous 
NaHCO3 (1 mL). The layers were separated and the organic layer was washed with brine (1 mL), dried over 
MgSO4 and concentrated under reduced pressure. Without further purification the residue was dissolved 
in dry MeCN (15 mL), 10 (530 mg, 3.02 mmol) was added and the mixture was cooled to -30 oC. Sn(OTf)2 
(50.4 mg, 0.12 mmol) was added and the mixture was allowed to warm up to RT overnight. The mixture 
was dilute with EtOAC (50mL) and quenched with sat. aq. NaHCO3 (1 mL). The layers were separated and 
the organic layer was dried over MgSO4 and concentrated under reduced pressure. The resulting residue 
was purified by column chromatography (EtOAc:heptane = 1:3) to yield 392 mg of a white solid of 13 (0.95 
mmol, 79%) with recovery of 41 mg starting material 12 (0.12 mmol, 10 %). RF = 0.49 (1:1, EtOAc:heptane); 
1H NMR (500 MHz, CDCl3) δ 7.35 (q, J = 8.9, 7.6 Hz, 10H), 5.33 – 5.04 (m, 4H), 4.91 (m, 1H), 4.68 (dp, J = 
11.2, 3.9 Hz, 1H), 2.99 – 2.40 (m, 2H), 2.30 (s, 1H), 2.24 – 1.75 (m, 3H), 1.76 – 1.61 (m, 3H), 1.57 – 1.50 (m, 
1H), 1.47 – 1.24 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 172.7, 136.6, 128.8, 128.6, 128.5, 128.2, 128.0, 67.6, 
67.2, 53.5, 46.7, 45.8, 30.4, 30.2, 26.3, 15.7; HRMS (ESI+): calcd for C2213C2H27NNaO5 (M+Na+): 434.1854, 
found 434.1857. 
 
(2S)-6-(2-Oxopropyl-1,3-13C2)piperidine-2-carboxylic acid [14] 
To a degassed solution of 9 (382 mg, 0.90 mmol) in MeOH:water (7 ml, 6:1) was added Pd/C (15 mg, 0.14 
mml, 10 mol% Pd). The atmosphere was exchanged to hydrogen and the suspension was stirred for 4 h. 
The reaction mixture was filtered over Celite, concentrated under reduced pressure. The product was 
purified by chromatography on Iatro beads (0 -> 40% MeOH in DCM) and lyophilized to obtain 128 mg of 
14 (0.68 mmol, 76%) as a white powder. 1H NMR (500 MHz, D2O) δ 3.66 (dd, J = 12.4, 3.3 Hz, 1H), 3.60 
(ddq, J = 12.5, 6.3, 3.2 Hz, 1H), 3.24 – 2.80 (m, 2H), 2.33 – 2.23 (m, 1H), 2.27 (dd, 1JCH = 128.3, 3J = 1.7 Hz, 
3H), 2.05 – 1.86 (m, 2H), 1.73 – 1.40 (m, 3H); 13C NMR (126 MHz, deuterium oxide) δ 60.2, 45.6, 45.5, 41.2, 
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